Albatroz Therapeutics Pte Ltd. has secured $3 million in seed funding to develop therapeutic antibodies against a new target that degrades the extracellular matrix, a key contributor to cancer and arthritis.
Albatroz Therapeutics Pte Ltd. has secured $3 million in seed funding to develop therapeutic antibodies against a new target that degrades the extracellular matrix, a key contributor to cancer and arthritis.
DUBLIN – As its name suggests, Glycoera AG aims to kickstart a new era in protein glycoengineering, and it has closed a CHF45 million (US$49 million) series A round to further its ambition of developing biologic drugs with defined glycosylation profiles that are an intrinsic aspect of their mechanisms.
Australian researchers at the Walter and Eliza Hall Institute of Medical Research in Melbourne have developed new yeast- and antibody-based methods to determine how tryptophan C-mannosylation, an unusual protein glycosylation modification, impacts the stability and function of disease-relevant proteins.
Targeting glycosylated PD-1 immune checkpoint may be a promising new cancer immunotherapeutic strategy, according to a collaborative study led by Taiwanese researchers, which was reported online in Cancer Research.
Targeting glycosylated PD-1 immune checkpoint may be a promising new cancer immunotherapeutic strategy, according to a collaborative study led by Taiwanese researchers, which was reported online in the March 10, 2020, edition of Cancer Research.
